Oxytocin on HR in Sleep Apnea Patient

Status Completed

Clinical Trial Summary

In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. OSA is a very prevalent disease with high cardiovascular risk factors, yet this disease remains very poorly treated. This proposal, based on the current literature and new basic science results detailed above on the role of oxytocin in cardiovascular control, will test if oxytocin administration improves adverse cardiovascular events during the recurrent nocturnal apneas in patients with OSA. This project will lay the groundwork and provide preliminary data to obtain NIH funding to test this important hypotheses more thoroughly and in larger clinical trials. This study will explore if intranasal oxytocin has any positive cardiovascular benefits in patients with sleep apnea.

Clinical Trial Description

Cohort A: 8 Subjects 8 Subjects that have recently undergone either a standard "in the sleep-lab" diagnostic polysomnography or an "at home" PSG test and have been diagnosed with OSA will be recruited into the research study where we will assess the beneficial effects of oxytocin treatment. These 8 subjects will undergo an "in the sleep-lab" diagnostic polysomnography that would be identical to the one they had for standard of care medical guidelines if they were diagnosed with OSA "in the sleep-lab". This research polysomnography should be performed within 4 weeks of their OSA diagnosis PSG. These 8 subjects will undergo another "in the sleep-lab" diagnostic polysomnography that is identical to the one that they had for standard of care to diagnose OSA. Within one hour prior to the research polysomnography the subjects will be given oxytocin (40 IU) intranasally. Outcome measures will be assessed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02564068
Study type	Interventional
Source	George Washington University
Contact
Status	Completed
Phase	Early Phase 1
Start date	May 22, 2015
Completion date	December 31, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05582070` - Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction	N/A
Recruiting	`NCT03919955` - A Novel Pharmacological Therapy for Obstructive Sleep Apnea	Phase 2
Completed	`NCT03927547` - Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders	N/A
Recruiting	`NCT04007380` - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI	N/A
Completed	`NCT02188498` - Electrocardiography Data Analysis in Sleep Disorders
Completed	`NCT01503164` - Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism	N/A
Recruiting	`NCT00747890` - Surgical Treatment of Mild Obstructive Sleep Apnea	N/A
Active, not recruiting	`NCT00738179` - Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease	Phase 3
Completed	`NCT00841906` - Alice PDx User/Validation Extended Trial	N/A
Completed	`NCT00202501` - Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome	N/A
Completed	`NCT00047463` - Effects of Treating Obstructive Sleep Apnea in Epilepsy	Phase 2
Not yet recruiting	`NCT06029881` - Portable System for Non-intrusive Monitoring of Sleep
Recruiting	`NCT06093347` - Central Apnoea Monitor Study
Terminated	`NCT05445869` - Severe OSA Study (SOS)	N/A
Withdrawn	`NCT04096261` - The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
Recruiting	`NCT04575740` - Phenotyping Mechanistic Pathways for Adverse Health Outcomes in Sleep Apnea	N/A
Completed	`NCT04676191` - Validation of a Contactless Vital Signs Measurement Sensor	N/A
Recruiting	`NCT06015620` - Comorbidities Resolution After MGB Surgery and Change in Body Composition
Completed	`NCT06051097` - Metabolic Syndrome and Obstructive Sleep Apnea
Completed	`NCT05687097` - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury